Showing posts with label insulin supplies. Show all posts
Showing posts with label insulin supplies. Show all posts

Tuesday, 20 May 2025

How Do You Make Sure You Never Forget Your Insulin at Home?

From healthcentral.com

Influencer Mila Clarke shares her go-to strategy for toting her T1D supplies 

Mila Clarke, 35, is a diabetes patient advocate, board-certified integrative nutrition diabetes health coach, author, and self-taught cook living with type 1 diabetes. The native Texan started her Hangry Woman food blog after being diagnosed with diabetes in 2016 and later launched the Glucose Guide Community app to help fellow warriors build confidence and knowledge around diabetes self-management. Follow her @thehangrywoman, where she covers everything from food joy and cooking to self-care from the perspective of “your diabestie.” 


How do you make sure you never forget your insulin at home?

I wish I could say I never forget my insulin, but let me tell you about the time I went to brunch, blood sugar climbing, and realized my pen was having a quiet day on the kitchen counter.

Nowadays, because I’m using an Omnipod 5 insulin pump, my insulin is always mostly attached to me. So I don’t have the same worries.

Since then, I’ve created a “leave-no-insulin-behind” ritual. It’s a lot like the “phone, wallet, keys” ritual, but it’s to keep me alive. I keep a little diabetes go-bag that’s always stocked with a spare pen and pen needles, a spare pod, vial, syringes, test strips, sanitizing spray, and low snacks. It lives in my purse, and I check it before I leave the house because it’s literally my lifeline.

I’m a little fashionista, so I love changing bags with each outfit, and I make sure that one go-bag is always with me no matter what—even if it means my boyfriend has it tucked away in his suit jacket on fancy nights.

Life happens. But a bit of prep makes it so much easier to handle the chaos. And a little advice? Prep before you’re on the go. When you’re ready to leave, you may be rushing, and I find that’s when I become the most forgetful!

https://www.healthcentral.com/condition/type-1-diabetes/how-do-you-make-sure-you-never-forget-your-insulin-at-home

Thursday, 12 September 2024

Weekly Insulin Injections As Effective for Diabetes as Daily Shots, Studies Show

From healthday.com

Key Takeaways

  • A new form of weekly insulin can control type 1 and type 2 diabetes as well as daily injections

  • The weekly shot involves a new class of insulin called efsitora

  • Such shots would allow for easier control of blood sugar than daily jabs, researchers say


Weekly insulin shots can help control both type 1 and type 2 diabetes as well as daily injections do, a pair of clinical trials have found.

A new class of insulin called efsitora alfa has been designed to require injections only once a week, researchers said.

Two phase 3 trials presented Tuesday at the European Association for the Study of Diabetes annual meeting in Madrid show that efsitora is as safe and effective as standard daily insulin shots:

  • One trial in 928 people with type 2 diabetes found that weekly efsitora controlled blood sugar levels as well as a long-acting form of insulin called degludec.

  • The other trial found that once-weekly efsitora also performed as well as daily degludec in 623 people with type 1 diabetes.

“A once-weekly insulin has the potential to simplify dose administration and diminish barriers to starting insulin therapy by means of a reduction in injection burden as compared with a once-daily insulin,” wrote the team behind the type 2 diabetes trial, which was led by Dr. Carol Wysham, an endocrinologist with the MultiCare Rockwood Center for Diabetes and Endocrinology in Spokane, Wash.

"Traditionally, basal insulins are dosed once a day -- a treatment schedule that can make compliance difficult for a significant portion of people living with type 2 diabetes," said Wysham said in a news release from drug maker Eli Lily. "Efsitora has the potential to address treatment burden and improve adherence -- all while lowering A1C. These results can make a significant impact for people living with type 2 diabetes looking for a once-weekly option that provides similar outcomes as daily insulins."

In both clinical trials, which lasted 52 weeks, researchers randomly assigned participants to taking either efsitora or degludec insulin.

The major difference in the results between the two trials involved hypoglycemic (low blood sugar) events.

The type 2 diabetes trial found no statistically significant difference between efsitora and degludec when it came to hypoglycemia.

But hypoglycemia occurred more often for type 1 diabetics taking efsitora (10%) compared with degludec (3%), results show.

More work is needed to figure out the best dose “to maintain efficacy while mitigating the risk of hypoglycemia with weekly efsitora treatment in people with type 1 diabetes,” concluded the type 1 diabetes trial team led by Dr. Richard Bergenstal, executive director of the HealthPartners Institute's International Diabetes Center in Minneapolis.

"People with type 1 diabetes need insulin every day. Currently, they can deliver the insulin using an automated insulin delivery system or by taking a daily basal insulin injection and multiple mealtime insulin injections each day," Bergenstal explained in an Eli Lilly news release. "This new data shows that with one dose a week of basal insulin, efsitora was able to achieve a similar A1C reduction as taking an injection of one of the most used background insulins every day. I look forward to further evaluation of these data, including ways to minimize hypoglycemia, so once-weekly insulin can be one option for personalizing the management of type 1 diabetes."

The type 2 diabetes trial also found that efsitora worked well in diabetics even if they were taking a GLP-1 drug like Ozempic.

“Given treatment guidelines and recommendations to incorporate GLP-1 receptor agonists earlier in treatment, along with their growing use worldwide, it is relevant to show that efsitora can be effectively and safely added to such therapy,” Wysham’s team concluded in a meeting news release.

Type 1 diabetes is an inherited condition in which the immune system destroys or damages the body’s ability to make insulin. People with type 2 diabetes develop resistance to insulin, which also can destroy or damage the ability to make insulin.

Results from the type 2 diabetes trial were published Sept. 10 in the New England Journal of Medicine, while results from the type 1 trial were published Sept. 10 in The Lancet.

https://www.healthday.com/health-news/diabetes/weekly-insulin-injections-as-effective-for-diabetes-as-daily-shots-studies-show 

Monday, 23 May 2022

New partnership provides affordable insulin for all in the USA

From jdrf.org.uk

An historic deal has been agreed between JDRF International and partners, to deliver lower-cost insulin across the USA from 2024 to everyone – regardless of insurance status.

The cost of a vial of insulin has tripled in the USA over the last ten years, with prices currently ranging from between $175 (£130) and $300 (£224) per vial, which could cost a person up to $1,000 (£750) a month. 

An estimated one in four people who are insulin dependent say they skip or ration their insulin because they cannot afford to pay this inflated price, potentially leading to severe consequences for their health, medical emergencies, or even death. 


This ground-breaking partnership between JDRF International – who are based in the USA – and other funders, means that Civica, a non-profit generic drug manufacturing company, can manufacture and distribute biosimilar insulin for no more than $30 (£23) a vial, or $55 (£40) for a box of five pen cartridges. This is as much as 90% lower than existing costs. 

To make this happen, JDRF International has agreed to underwrite the initial development costs, meaning that Civica is able to provide this low-cost option to people who need it. 

Civica will develop biosimilars to three of the most commonly used insulins in the USA, to reach the most people possible: glargine (Lantus®), lispro (Humalog®), and aspart (Novolog®). Biosimilar insulin is highly similar to existing insulins that are already licensed for use and are just as effective. 

These affordable insulins will be available from 2024 to allow time for development, clinical trials and FDA approval, amongst other logistical factors. Everyone – regardless of their health insurance status – will be able to access this affordable insulin at this cost. This distinguishes this programme from many other existing routes of access for affordable insulin. 

JDRF UK’s Chief Executive, Karen Addington, said: “We are today proud of the impact that JDRF achieves: this partnership will help resolve some of the systemic health inequality for people living with type 1 diabetes in the USA. 

“It is our hope that this initiative then has the potential to go on and save lives across the world. We know that this news today will resonate with so many of our supporters and stakeholders who live with type 1 or work to prevent, treat and cure type 1 diabetes.”

Read JDRFI’s press release


https://jdrf.org.uk/news/jdrf-announces-support-of-civica-to-manufacture-and-distribute-low-cost-insulin/ 

Monday, 1 March 2021

A new approach for handling insulin could revolutionize diabetes treatment for millions of people

From businessinsider.com

For people living with diabetes in the developing world, a lack of electricity can hamper access to insulin. But a project in Kenya has shown that insulin can be maintained in hot climates without refrigeration. Researchers, calling it a breakthrough, are urging the World Health Organization to amend its guidelines. 

For people living with diabetes in the developing world, getting daily life-sustaining doses of insulin has gone hand in hand with access to electricity.

Once a vial is opened, manufacturers recommend storing it in a refrigerator until it expires, which is usually after four weeks. But an estimated 470 million people around the world who don't have access to electricity and fridges for food and medicine, making it difficult to store insulin at home.

But now, a new program could help revolutionize treatments around the world. 

It started at the Dadaab refugee camp in northern Kenya, where temperatures can reach up to 99 degrees Fahrenheit and many have no access to refrigeration. As a consequence, patients' lives have practically revolved around going to and from the hospital to receive insulin. Having diabetes could mean missing school, work, especially since the camp's curfew restricts when it's possible to make the trek.

When doctors working in the camp noticed more and more patients coming to the hospital with complications from their diabetes, they reached out to researchers at the University of Geneva and decided to monitor at-home insulin storage at the camp, which experienced much warmer temperatures than label recommendations. 

Researchers replicated the camp's daily temperature, which ranged from 77 to 99 degrees Fahrenheit, in the lab, and tested the insulin's effectiveness. They also studied leftover insulin from vials that patients had used after storing them in their homes.

They discovered that even without refrigeration, insulin kept at the camp's tropical temperatures was safe to use for four weeks — a revelation that could be life-changing for diabetes patients around the world. 

Following their investigation, the team adjusted the advice they were giving patients, teaching them how to self-inject, check their own blood sugar, and what danger symptoms to look out for. Most exciting of all, they showed patients how to store the insulin at home using a plastic container with a wet towel around it.  

What followed was a dramatic drop in the number of diabetic patients coming to hospital with acute complications. They were able to go to work and school and "not spend all day seeking out healthcare to stay alive," said Philippa Boulle, from the Médecins Sans Frontières (MSF, also known as Doctors Without Borders).

Even though insulin can be damaged when it's stored at high temperatures, the researchers found that cooler temperatures overnight could keep the insulin safe.

"Every protein goes towards degradation when it's heated, but there are proteins that can go back when you cool them down again, and insulin seems to be one of them," Leonardo Scapozza, a professor at the University of Geneva's School of Pharmaceutical Sciences and one of the researchers who worked with doctors in the Dagahaley camp, told Insider. 

At the moment, guidance says patients can store their insulin at an "'ambient temperature'," but Scapozza said "and hot settings" should be added for clarification. There only needs to be three words added to that: 'and hot settings', Scapozza says.

He said the findings could also be applied to high-income countries such as the US, for example, when natural disasters and storms that cut off power supplies.

The researchers have done further studies to test insulin in different climates, and are helping supporting refugees in their South Sudan setting to take insulin home, too.  

Now, MSF is calling on pharmaceutical corporations to amend guidelines, and for the World Health Organization to endorse their findings.

While there have been many studies testing how stable insulin is at different temperatures, the oscillating temperature factor in this study is a "new twist," says Gojka Roglic, a medical officer at the WHO responsible for activities on diabetes management, told Insider.

WHO won't be making any recommendations based on this study alone, but Roglic  said it will be included in a review of all research later this year.  

Ali Bishar, who is in charge of MSF's insulin management program at the Dadaab refugee camp in Kenya, said education on diabetes and insulin is "paramount" to the program working.

"After they're trained, the patients have to pass a competency test. Then they're given their insulin and care is provided on and outside the wards," Bashar said, adding that the program, which started in 2015, has grown from 35 to 45 patients in the last six years.

However, insulin storage is only the start of  managing diabetes in low-resource settings. Another major concern is how a poor diet can contribute to patients' symptoms. 

"You have to have food when you inject insulin. In some settings, patients are fearful of the injection if they haven't had a meal that day," Boulle says.

Rahmo, who was in the first cohort of patients to start the MSF programme in 2015, told Insider that she has challenges with getting enough food and having a good diet., But regardless of her diet, Rahmo said  her health has improved. 

"Before this, I was confused about how to continue my life and if I'd survive," she  told Insider through an interpreter.  "Today, I'm very happy to control my diabetes at home." 

Mohamed test

Mohamed Hussein Bule, 27, who teaches science at a refugee camp in Kenya.   

Paul Odongo for MSF                        

Mohamed Hussein Bule, 27, a refugee from Somalia who works as a teacher at a primary school in Dagahaley, enrolled in the MSF program in 2015. 

He was diagnosed with diabetes in 2014 after his weight plummeted from 150 pounds to 82 pounds, but since joining the program his weight is back up to about 143 pounds.

"I was supposed to pick up insulin at the hospital early in the morning to take home, then go to work. I was missing a lot of classes. Now, I take a vial in the morning and record my glucose, and continue with the program as my day continues," he said. 

"I don't even feel like a patient with diabetes now. I'm very glad to be on the program."

https://www.businessinsider.com/changing-insulins-storage-protocol-revolutionizes-diabetes-treatment-2021-2?r=US&IR=T

Monday, 21 December 2020

For UK Diabetics: Diabetes and Brexit

From diabetes.co.uk

As European Union (EU) trade deals continue to be negotiated, people with diabetes are understandably getting worried about how Brexit might impact receiving their medication and insulin.

We’ve put together this page of information to keep you informed as the process continues.

How could Brexit affect diabetes medication?

Although the UK is no longer officially part of the EU, the country is currently in a transition period which means fine details are still being discussed. At the moment how we trade insulin and other medicines with the EU is still being negotiated.

This transition period will end on 31 December 2020 and if an agreement has not been reached, then the default position of a no-deal Brexit will come into force on 1 January 2021. If this happens then it could mean the process of trading medication with the EU will become complicated which might impact insulin supplies into the UK.

Despite this, the Government says it does not expect insulin supplies to be disrupted as contingency plans have been put in place. We will continue to monitor this issue and keep you informed of any developments.

What is being done?

According to the Department for Health and Social Care, the Government has been working on trying to find a mutual agreement with the EU on medicines.

It is thought that the three main insulin suppliers, Lilly, Sanofi and Novo Nordisk, have kept at least six weeks stock of insulin in the UK to reduce potential disruption.

Other diabetes medicines

The Government is urging other pharmaceutical companies that supply diabetes medications to also retain stocks just in case a disruption should occur. This is to ensure most people have access to their medication should a no-deal Brexit go through.

However, many diabetes medicines are made by UK companies so it is unlikely there will be any disruption for them.

In the meantime, we recommend people who use insulin or other diabetes medicines to contact their GP and order their repeat prescription at least 14 days before collection. There is no need to stockpile though as this could put other people at risk if they are unable to access the treatment they require.

What about diabetes technology?

 The Department of Health and Social Care has confirmed that medical devices, which include diabetes technologies, are also included in the planning for both a deal and no-deal outcome.

Good news for those who use the Abbot FreeStyle Libre as that is made in the UK, so therefore should not be affected.

For those who use pumps or a continuous glucose monitor we recommend keeping a back-up supply of pen needles, lancets and test strips just in case there is a delay in those parts coming into the country.

Healthcare abroad 

After 31 December, the European Health Insurance Card (EHIC) can no longer be used when abroad in the EU so we recommend ensuring you have travel insurance that fully when travelling overseas.

https://www.diabetes.co.uk/diabetes-and-brexit-2020/

Tuesday, 24 September 2019

In a first, drone delivers diabetes medicine to remote island

From theweek.com

For people who rely on insulin, it's scary to think about what might happen if they are suddenly unable to pick up their medication.

That's one reason why developers at the National University of Ireland, Galway, designed a special drone that can deliver life-saving medications to people on remote islands. Researchers wanted to ensure that if normal delivery channels are down, due to severe weather or other catastrophic events, supplies could still get to people in need.

The team said this was the first time an autonomous drone has ever flown across the north Atlantic Ocean. The drone went from Galway to the Aran Islands in western Ireland, traveling across roughly 11 miles of water in 15 minutes. During the entire flight, the drone was connected to the internet, and the Irish Aviation Authority's air space regulators were in contact, the Irish Times reports. Marion Broderick is a doctor on the Aran Islands, and she told the Times this technology offers "endless possibilities." Catherine Garcia

Wednesday, 11 September 2019

Brexit and Diabetes – how could a no-deal Brexit affect people with diabetes?

From blogs.diabetes.org.uk

If you’re living with or affected by diabetes, we know you might be worried about how Brexit might affect things like your diabetes medicines, in particular insulin. 
In this blog, we cover the potential impact of a no-deal Brexit, what’s happening across England, Scotland, Wales and Northern Ireland, and how here at Diabetes UK we’re getting your voice heard.  
We will keep updating you as events develop in the next two months. But we want to hear from you – use our online form to ask us more questions.

What has Diabetes UK been doing?

Earlier this year, following a series of letters and public statements, along with JDRF, we had a meeting with senior officials with expertise in logistics and supplies of medicines and consumables at the Department of Health and Social Care and NHS England.
Recently we have been raising your concerns directly with officials in various meetings. Most recently, we attended a meeting with senior officials within DHSC and NHS England with responsibility for ensuring supply of medicines in the event of a no-deal Brexit continuation of supply of medicines.

At this meeting we were further assured about being prepared for the possibility of a no-deal Brexit, including the supply of insulin.
Following the appointment of the new Prime Minister, we’ve written to seek his assurances on continued, uninterrupted access to insulin in the event of a no-deal Brexit.
We’ve been clear that, alongside assurances to date, the government should continue to make sure that information about progress of its plans is made available to the public.
We will continue to engage with senior officials to ensure we are able to share up-to-date information with you as 31st October approaches.

What have the government said about its plans and preparations?

The UK Government intends to leave the EU on the 31st October 2019. While leaving the EU with a deal remains its priority, they are planning for every eventuality, including ‘no-deal’. But what does this really mean and how might it affect you?
The government has said that the capacity that is available for importing goods will be prioritised, to make sure people have access to the medicines they need.
Recent announcements from the government have outlined that they are preparing by:

.     Putting plans in place that include additional stocks of medicines, strengthening the process and resources used to deal with shortages if they happen,
  • Securing freight capacity. The Department for Transport are leading a procurement exercise that will set up a framework to access secure additional ‘roll-on, roll-off’ freight capacity. The aim is to support supplier contingency plans to re-route their supply chains away from the Channel short straits. Medicines and medical products will be prioritised on any further capacity gained through this process.
  • The Department of Health and Social Care (DHSC) is setting up a ‘Dedicated Health Channel’. This will be an express freight service that will be able to bring medicines and medical products into the UK within 24 to 72 hours if needed after 31st October. This is designed to support the uninterrupted supply of medicines and medical products where there is an urgent need or where a suppliers’ own plans are disrupted or delayed. This service will be able to refrigerate products, and so would be able to import insulin in the event of shortages.
  • Health ministers are regularly attending an EU Exit Operations committee, which discusses operational issues in preparation for Brexit such as continuity of supply of medicines. The DHSC is also centrally coordinating contingency measures to mitigate risks to supply. They say this removes the need for any stockpiling at local level which could cause medicine shortages and put patient care at risk.
  • Working closely with all suppliers of medicines and devices to ensure uninterrupted supply in the event of a no-deal Brexit.
  • You can find all of the EU Exit-related publications from the DHSC at GOV.UK

    What is the situation in Scotland?

    In April, our colleagues in Scotland met with the Principle Pharmaceutical Officer, Prof Alison Strath, and the lead civil servant for provision of medicines and were reassured that contingency plans were in place at that time.  With the fresh focus on the possibility of a no-deal Brexit in recent weeks, Diabetes Scotland has been back in contact with Prof Strath and the Scottish Government to seek an update. The Scottish Government has now established a NHS Scotland Medicines Shortages Response Group to ensure that UK wide plans are carried out effectively in Scotland.
    Get more information at gov.scot

    What is the situation in Wales?

    Diabetes UK Cymru has been working with the Welsh NHS Policy Confederation to raise issues with the Welsh Government as a result of a no-deal Brexit.
    We’ve raised concerns about potential post-Brexit scenarios with the ABPI (Association of the British Pharmaceutical Industry) representative in Wales and the Welsh Government’s Cabinet Secretary for Health, Social Care and Sport.

    What is the situation in Northern Ireland?

    The Department of Health in Northern Ireland has published more information about the EU exit. This includes guidance from the Department, as well as links to letters issued by the department to GPs, pharmacists, opthalmologists and other healthcare professionals.

    What impact will there be on insulin supplies specifically?

    Earlier this year we wrote to the three main insulin manufacturers – Lilly, Novo Nordisk and Sanofi – to understand what contingencies and additional stocks they planned to have in place. This month we wrote back to them to check the situation again.
    All three have confirmed that these are still in place, and the manufacturers tell us they have gone beyond the recommendations made by the government – they are keeping at least 16 weeks of additional stock. People should continue to get prescriptions and use their medicines in the normal way.

    What about my diabetes tech?

    The government have said they are in contact with key medical technology companies. We are seeking assurances about supplies and stocks of key pieces of technology and diabetes equipment. We have asked the government to clarify that their work includes having regular discussions with all the major companies who provide continuous glucose monitors (CGM), flash glucose monitors (we call it Flash for short), insulin pumps and blood glucose monitoring technology. When we have received a response we will update this blog.

    What if I’m travelling out of the UK after Brexit?

    The government has said that access to healthcare in EU countries will change if there is a no-deal Brexit, as European Health Insurance Cards may not be valid. Anyone travelling to the EU, EEA or Switzerland should get health insurance to cover this. UK nationals who live in EU countries will also have new arrangements.
    The advice may also vary depending on the country – find out more from the NHS website.

    https://blogs.diabetes.org.uk/?p=11050&utm_source=bronto&utm_medium=email&utm_term=Read+our+Brexit+blog&utm_content=Read+our+Brexit+blog&utm_campaign=Enewsletter+September+2019